浙江冠科博创生物制药

Zhejiang Crown Bochuang Biopharma Co., Ltd. (Crown Bochuang) is a China-based clinical-stage biopharmaceutical company and a wholly-owned subsidiary of Apollomics Inc. (NASDAQ: APLM). Established in May 2020 and headquartered in Hangzhou, China, the company focuses on the discovery and development of novel oncology therapies, including tumor inhibitors and immuno-oncology agents. Its pipeline features APL-102, an oral small molecule multi-kinase inhibitor targeting VEGFR, MAPK (B-RAF/C-RAF), and CSF1R, which is currently in Phase 1 clinical development for advanced solid tumors. Through its parent company Apollomics, Crown Bochuang is also associated with the development of vebreltinib (APL-101), a highly selective c-Met inhibitor approved in China, and geptanolimab (APL-501), an anti-PD-1 monoclonal antibody.